MediXall Group, Inc.
MDXL
$0.0039
$0.000411.43%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 73.79% | 170.38% | 421.75% | 296.57% | 239.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 73.79% | 170.38% | 421.75% | 296.57% | 239.39% |
| Cost of Revenue | -31.19% | -46.04% | -61.17% | -62.23% | -63.47% |
| Gross Profit | 46.50% | 60.75% | 70.30% | 69.32% | 69.15% |
| SG&A Expenses | -44.28% | -28.78% | -11.27% | 2.74% | 5.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -993.94% | -993.94% |
| Total Operating Expenses | -37.84% | -33.09% | -33.77% | -35.69% | -35.95% |
| Operating Income | 42.66% | 38.32% | 38.04% | 40.13% | 39.73% |
| Income Before Tax | 34.18% | 32.14% | 33.19% | 28.76% | 29.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 34.18% | 32.14% | 33.19% | 28.76% | 29.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.18% | 32.14% | 33.19% | 28.76% | 29.36% |
| EBIT | 42.66% | 38.32% | 38.04% | 40.13% | 39.73% |
| EBITDA | 42.82% | 38.44% | 38.21% | 40.67% | 40.25% |
| EPS Basic | 37.84% | 36.53% | 37.58% | 33.07% | 33.53% |
| Normalized Basic EPS | 36.55% | 35.44% | 37.01% | 39.69% | 39.56% |
| EPS Diluted | 35.06% | 28.49% | 31.00% | 31.35% | 35.02% |
| Normalized Diluted EPS | 36.55% | 35.44% | 37.01% | 39.69% | 39.56% |
| Average Basic Shares Outstanding | 9.97% | 10.19% | 9.43% | 9.68% | 9.32% |
| Average Diluted Shares Outstanding | 9.97% | 10.19% | 9.43% | 9.68% | 9.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |